Enovis Above-Market Growth Potential Surge Would Come from Market Share Gains and Accretive Acquisitions: Analyst

Needham initiated coverage on Enovis Corp ENOV with a Buy and a price target of $70, noting that the company can sustain above-market growth in its Reconstructive segment via market share gains and acquisitions, which is expected to be accretive to earnings

The analyst says that Enovis has significant room for gross, operating, and EBITDA margin improvement and views the stock as an attractive valuation.

ENOV's Reconstructive business is its growth engine, and management expects to sustain 10-15% growth driven primarily by market share gains. 

Management is targeting >50 bps of EBITDA margin improvement annually, and product mix shifts alone will drive 20-30 bps of gross margin improvement and 10 bps of EBITDA margin improvement annually, the analyst says.

The analyst expects that M&A to remain a part of the company's strategy and notes that it ended 1Q23 with $22M of cash and $285 million of debt with an estimated leverage ratio (debt/EBITDA) of 1.2x. 

Needham notes that Enovis can finance up to $650-700 million of M&A with debt before reaching its maximum allowed leverage ratio of 4.0x. It may target high-growth, high-margin businesses and expect future deals to be accretive to earnings.

Price Action: ENOV shares are up 1.94% at $61.02 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CareInitiationAnalyst RatingsGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!